Are you Dr. Johnson?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 44 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1120 15th St
# CN-4141A
Augusta, GA 30912Phone+1 706-721-3626Fax+1 706-721-4804
Summary
- Dr. Theodore Johnson, MD is a pediatric hematologist/oncologist in Augusta, Georgia. He is currently licensed to practice medicine in Georgia, Ohio, and South Carolina. He is affiliated with WellStar MCG Health, affiliated with Medical College of Georgia and is an Assistant Professor at Medical College of Georgia at Georgia Health Sciences University.
Education & Training
- Cincinnati Children's Hospital Medical CenterFellowship, Pediatric Hematology/Oncology, 2007 - 2010
- Medical College of GeorgiaResidency, Pediatrics, 2004 - 2007
- Medical College of Georgia at Augusta UniversityClass of 2004
Certifications & Licensure
- GA State Medical License 2010 - 2026
- SC State Medical License 2006 - 2017
- OH State Medical License 2007 - 2012
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children Start of enrollment: 2010 Jan 01
- Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG Start of enrollment: 2019 Oct 02
Publications & Presentations
PubMed
- 279 citationsCells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell ResponsesAndrew L. Mellor, Derin B. Keskin, Theodore S. Johnson, Phillip Chandler, David H. Munn
Journal of Immunology. 2002-04-15 - 71 citationsHost Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor ToleranceTheodore S. Johnson, David H. Munn
Immunological Investigations. 2012-09-27 - 13 citationsModulation of Tumor Tolerance in Primary Central Nervous System MalignanciesTheodore S. Johnson, David H. Munn, Bernard L. Maria
Clinical & Developmental Immunology. 2012-01-24
Press Mentions
- Novel Immunotherapy Beneficial to Children with Relapsed Brain Tumours: ResearchApril 25th, 2023
- Novel Treatment Regimen Appears Well Tolerated, Beneficial to Children with Relapsed Brain TumorsApril 25th, 2023